DK382986A - Aktivering af makrofag tumoricid aktivitet med granulocytmakrofag kolonistimulationsfaktor - Google Patents

Aktivering af makrofag tumoricid aktivitet med granulocytmakrofag kolonistimulationsfaktor Download PDF

Info

Publication number
DK382986A
DK382986A DK382986A DK382986A DK382986A DK 382986 A DK382986 A DK 382986A DK 382986 A DK382986 A DK 382986A DK 382986 A DK382986 A DK 382986A DK 382986 A DK382986 A DK 382986A
Authority
DK
Denmark
Prior art keywords
granulocyte
stimulating factor
colony stimulating
macrophag
macrophage colony
Prior art date
Application number
DK382986A
Other languages
English (en)
Other versions
DK174603B1 (da
DK382986D0 (da
Inventor
Dirk M Anderson
Michael A Cantrell
Douglas P Cerretti
Iii Paul J Conlon
David J Cosman
Kenneth H Grabstein
Alf D Larsen
Virginia L Price
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27117812&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK382986(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of DK382986D0 publication Critical patent/DK382986D0/da
Publication of DK382986A publication Critical patent/DK382986A/da
Application granted granted Critical
Publication of DK174603B1 publication Critical patent/DK174603B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK198603829A 1985-08-16 1986-08-11 Anvendelse af granulocyt makrofag kolonistimulerende faktor til fremstilling af et medikament til fremme af tumoricid aktivitet DK174603B1 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US76689385A 1985-08-16 1985-08-16
US76689385 1985-08-16
US06/888,995 US5078996A (en) 1985-08-16 1986-07-31 Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US88899586 1986-07-31

Publications (3)

Publication Number Publication Date
DK382986D0 DK382986D0 (da) 1986-08-11
DK382986A true DK382986A (da) 1987-02-17
DK174603B1 DK174603B1 (da) 2003-07-14

Family

ID=27117812

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198603829A DK174603B1 (da) 1985-08-16 1986-08-11 Anvendelse af granulocyt makrofag kolonistimulerende faktor til fremstilling af et medikament til fremme af tumoricid aktivitet

Country Status (8)

Country Link
US (1) US5078996A (da)
EP (1) EP0211684B1 (da)
JP (1) JPH0780781B2 (da)
AT (1) ATE77958T1 (da)
AU (1) AU586876B2 (da)
CA (1) CA1341142C (da)
DE (1) DE3685918T2 (da)
DK (1) DK174603B1 (da)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2130493C1 (ru) * 1984-07-06 1999-05-20 Новартис Аг Способ получения белка с активностью gm-csf приматов
US5795568A (en) * 1984-09-19 1998-08-18 Novartis Corporation Method of treating infectious disease with GM-CSF
US5556620A (en) * 1985-02-05 1996-09-17 Cetus Oncology Corporation Use of recombinant colony stimulating factor-1 to enhance wound healing
US5837229A (en) * 1985-02-05 1998-11-17 Chiron Corporation Uses of recombinant colony stimulating factor-1
US5422105A (en) * 1985-02-05 1995-06-06 Cetus Oncology Corporation Use of recombinant colony stimulating factor 1
US5104650A (en) * 1985-02-05 1992-04-14 Cetus Corporation Uses of recombinant colony stimulating factor-1
US5093115A (en) * 1985-06-11 1992-03-03 The United States Of America As Represented By The Department Of Health And Human Services Method of preparing activated killer monocytes for treating colorectal cancer
US5391706A (en) * 1987-07-16 1995-02-21 Schering Plough Corporation Purification of GM-CSF
EP0318184A1 (en) * 1987-11-12 1989-05-31 Schering Corporation Acceleration of bone formation with GM-CSF
BE1002141A5 (fr) * 1988-01-13 1990-07-31 Bartholeyns Jacques Procede de culture et d'activation de cellules humaines et conditionnement pour le traitement du cancer.
JPH01193227A (ja) * 1988-01-29 1989-08-03 Res Dev Corp Of Japan 癌免疫療法補助剤
AU4219689A (en) * 1988-08-19 1990-03-23 Genetics Institute Inc. Treatment for malignant melanoma
GB8824591D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
DE69001686T2 (de) * 1989-01-30 1993-09-02 Schering Corp Behandlung von leukozytstoerungen mit gm-csf.
US5154921A (en) * 1990-07-13 1992-10-13 Dana-Farber Cancer Institute, Inc. Promotion of maturation of hematopoietic progenitor cells
US5199942A (en) * 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
US5637483A (en) * 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
US5904920A (en) * 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
US5292513A (en) * 1992-05-18 1994-03-08 Anthony G. Gristina Method for nonspecific cellular immune stimulation
US5662899A (en) * 1993-05-18 1997-09-02 I.D.M. Immuno-Designed Molecules Macrophages, process for preparing the same and their use as active substances of pharmaceutical compositions
US6001351A (en) * 1993-05-18 1999-12-14 I.D.M. Immuno-Designed Molecules Macrophages, process for preparing the same and their use as active substances of pharmaceutical compositions
US6540994B1 (en) * 1997-07-18 2003-04-01 I.D.M. Immuno-Designed Molecules Macrophages, process for preparing the same and their use as active substances of pharmaceutical compositions
JPH11509845A (ja) 1995-07-21 1999-08-31 アメリカ合衆国 造血多分化性細胞移植のための放射線または放射線類似作用化学療法の減少方法
US6267955B1 (en) 1995-09-15 2001-07-31 Yeda Research And Development Co. Ltd. Mononuclear phagocytes and their use to promote axonal regeneration
US5800812A (en) * 1995-09-15 1998-09-01 Yeda Research And Development Co. Ltd. Methods of use of mononuclear phagocytes to promote axonal regeneration
US5942253A (en) * 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
US6080409A (en) * 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
US5891432A (en) 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
EP1125133A1 (en) * 1998-11-03 2001-08-22 Cell Genesys, Inc. Novel cancer-associated antigens and methods of their identification
NZ515322A (en) * 1999-05-13 2004-03-26 Wyeth Corp Adjuvant combination formulations
CA2388337C (en) 1999-10-22 2013-01-08 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
US6911204B2 (en) 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
HK1052314A1 (zh) * 2000-08-11 2003-09-11 Favrille, Inc. 改变t细胞介导的病理的方法和组合物
IL155690A0 (en) * 2000-11-10 2003-11-23 Wyeth Corp Adjuvant combination formulations
US20070128229A1 (en) * 2002-04-12 2007-06-07 Wyeth Surface proteins of Streptococcus pyogenes
BR0208874A (pt) * 2001-04-13 2004-06-22 Wyeth Corp Proteìnas superficiais de streptococcus pyogenes
EP2277897A1 (en) 2001-04-16 2011-01-26 Wyeth Holdings Corporation Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
AU2003218162B2 (en) * 2002-03-15 2009-10-29 The Curators Of The University Of Missouri Mutants of the P4 protein of nontypable haemophilus influenzae with reduced enzymatic activity
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
US7301554B2 (en) * 2002-09-20 2007-11-27 Ricoh Company, Ltd. Light scanning device, scanning line adjusting method, scanning line adjusting control method, image forming apparatus, and image forming method
WO2004035086A2 (en) 2002-10-16 2004-04-29 Hunter Samuel F Method for treatment of demyelinating central nervous system disease using gm-csf
US20040197312A1 (en) * 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
WO2005020902A2 (en) * 2003-08-21 2005-03-10 Cytokine Pharmasciences, Inc. Compositions and methods for treating and diagnosing irritable bowel syndrome
KR101157694B1 (ko) 2003-12-17 2012-06-20 와이어쓰 엘엘씨 면역원성 펩티드 캐리어 컨쥬게이트 및 이의 제조 방법
JP4696079B2 (ja) 2003-12-17 2011-06-08 ヤンセン アルツハイマー イミュノセラピー Ａβ免疫原性ペプチド担体結合物およびそれの製造方法
CA2559652C (en) * 2004-03-15 2017-02-14 Sunesis Pharmaceuticals, Inc. Methods of using sns-595 in treating cancer
GB0410220D0 (en) 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
US7674456B2 (en) * 2004-06-14 2010-03-09 Charles Wiseman Breast cancer cell lines and uses thereof
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
CN101031323A (zh) * 2004-07-16 2007-09-05 尼克塔治疗亚拉巴马公司 Gm－csf部分与聚合物的缀合物
US20060062764A1 (en) * 2004-08-25 2006-03-23 Seshidar-Reddy Police Fiber-modified adenoviral vectors for enhanced transduction of tumor cells
US20060057127A1 (en) * 2004-09-10 2006-03-16 Pocheng Liu Cytokine-expressing cellular vaccines for treatment of prostate cancer
EP2298341A3 (en) 2004-10-21 2011-07-13 Wyeth LLC Immunogenic compositions of staphylococcus epidermidis polypeptide and polynucleotide antigens
WO2006050058A2 (en) * 2004-10-28 2006-05-11 The General Hospital Corporation Methods of detection and therapy of inflamed tissues using immune modulation
US20080193376A1 (en) * 2004-10-28 2008-08-14 The General Hospital Corporation Methods of Enhanced Detection and Therapy of Inflamed Tissues Using Immune Modulation
RU2271392C1 (ru) * 2004-11-15 2006-03-10 Институт Биоорганической химии им. акад. М.М. Шемякина и Ю.А. Овчинникова Российской Академии Наук РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pFGM17, КОДИРУЮЩАЯ ПОЛИПЕПТИД ГРАНУЛОЦИТАРНО-МАКРОФАГАЛЬНОГО КОЛОНИЕСТИМУЛИРУЮЩЕГО ФАКТОРА ЧЕЛОВЕКА, И ШТАММ БАКТЕРИЙ Escherichia coli BL21(DE3)/pFGM17 - ПРОДУЦЕНТ ПОЛИПЕПТИДА ГРАНУЛОЦИТАРНО-МАКРОФАГАЛЬНОГО КОЛОНИЕСТИМУЛИРУЮЩЕГО ФАКТОРА ЧЕЛОВЕКА
US8580814B2 (en) * 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
WO2007123737A2 (en) 2006-03-30 2007-11-01 University Of California Methods and compositions for localized secretion of anti-ctla-4 antibodies
US20070231298A1 (en) * 2006-03-31 2007-10-04 Cell Genesys, Inc. Cytokine-expressing cancer immunotherapy combinations
US7919079B2 (en) 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AU2007258280B2 (en) 2006-06-12 2013-05-02 Sunesis Pharmaceuticals, Inc. Compounds and compositions for treatment of cancer
EP3255141B1 (en) 2006-07-13 2021-12-01 Wyeth LLC Production of antibodies with improved glycosylation pattern
ES2541546T3 (es) 2006-11-03 2015-07-21 Wyeth Llc Sustancias que inhiben la glucólisis en cultivo celular
US20090285819A1 (en) * 2006-11-15 2009-11-19 Functional Genetics, Inc. Methods and compositions for treating influenza
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
AU2008223133A1 (en) 2007-03-02 2008-09-12 Wyeth Use of copper and glutamate in cell culture for production of polypeptides
WO2008109818A1 (en) * 2007-03-07 2008-09-12 Mayo Foundation For Medical Education And Research Treating cancer with granulocyte-macrophage colony stimulating factor
US20100255513A1 (en) * 2007-03-30 2010-10-07 Denson Lee A Serological markers of inflammatory bowel disease phenotype and disease progression
US20080267935A1 (en) * 2007-04-06 2008-10-30 Cell Genesys, Inc. AraC in combination with a cytokine-secreting cell and methods of use thereof
WO2009014708A2 (en) * 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
US8425897B2 (en) * 2007-08-30 2013-04-23 Immutep S.A. Compositions containing LAG-3 and cells that secrete GM-CSF and methods of use
RU2010124788A (ru) * 2007-12-21 2012-01-27 Ваейт ЭлЭлСи (US) Генетически модифицированный ослабленный вирус везикулярного стоматита, композиции и способы их применения
EP2650014A2 (en) 2008-06-20 2013-10-16 Wyeth LLC Compositions and methods of use of ORF1358 from beta-hemolytic streptococcal strains
MX2011004755A (es) * 2008-11-05 2011-10-10 Wyeth Llc Composicion inmunogenica multicomponente para la prevencion de enfermedad estreptococica beta-hemolitica (bhs).
SG10201406432RA (en) 2009-06-22 2014-11-27 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
SA110310528B1 (ar) 2009-06-22 2014-07-02 Wyeth Llc التركيبات المولدة للمناعة لأنتيجينات ستافيلوكوكس أوريس
EP2335730A1 (en) 2009-12-18 2011-06-22 Deutsches Krebsforschungszentrum Fusion polypeptides and their use for prevention and treatment of cancer
PL2575870T3 (pl) 2010-06-04 2017-05-31 Wyeth Llc Preparaty szczepionek
CN107913396B (zh) 2010-08-23 2022-03-08 惠氏有限责任公司 脑膜炎萘瑟氏菌rLP2086抗原的稳定制剂
AU2011300409B2 (en) 2010-09-10 2015-03-26 Wyeth Llc Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
EP2654784B1 (en) 2010-12-22 2016-12-07 Wyeth LLC Stable immunogenic compositions of staphylococcus aureus antigens
ITMI20111182A1 (it) 2011-06-28 2012-12-29 Canio Buonavoglia Vaccino per coronavirus canino
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MY198910A (en) 2012-03-09 2023-10-02 Pfizer Neisseria meningitidis compositions and methods thereof
HK1209140A1 (en) 2012-07-19 2016-03-24 Zoetis Services Llc Bovine influenza c virus compositions
WO2014018724A1 (en) 2012-07-27 2014-01-30 Zoetis Llc Tick toxin compositions
JP6502262B2 (ja) 2012-12-20 2019-04-17 ファイザー・インク 糖複合化方法
US9724366B2 (en) 2012-12-30 2017-08-08 Carmel-Haifa University Economic Corporation Ltd CD11 B[low] macrophages and conditioned media thereof for treating cancer and/or fibrosis
WO2014136064A2 (en) 2013-03-08 2014-09-12 Pfizer Inc. Immunogenic fusion polypeptides
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
EP2983703A1 (en) 2013-03-15 2016-02-17 Zoetis Services LLC Cross-protection of bovines against b. trehalosi infection by a multi-valent vaccine
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
WO2016130569A1 (en) 2015-02-09 2016-08-18 Mj Biologics, Inc. A composition comprising pedv antigens and methods for making and using the composition
CN106535930A (zh) 2014-03-11 2017-03-22 明尼苏达大学董事会 猪流行性腹泻病毒疫苗及其使用方法
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
WO2016132294A1 (en) 2015-02-19 2016-08-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
MX380387B (es) 2015-03-12 2025-03-12 Zoetis Services Llc Metodos de piolisina y composiciones.
MY182282A (en) 2015-05-04 2021-01-18 Pfizer Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
CA2995101A1 (en) 2015-08-14 2017-02-23 Zoetis Services Llc Mycoplasma bovis compositions
WO2017123201A1 (en) 2016-01-11 2017-07-20 Zoetis Services Llc Novel cross protective vaccine compositions for porcine epidemic diarrhea virus
US11033615B2 (en) 2016-05-31 2021-06-15 The Government of the United States, As Represented by the Secretary of the Army Fort Detrick, Maryland Zika virus vaccine and methods of production
HUE057035T2 (hu) 2016-10-05 2022-04-28 Zoetis Services Llc Liofilizálási eljárások, amelyek stabilan dhidratált egysejtûeket eredményeznek, potens élõ vakcinaként történõ alkalmazásra
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
GB201703529D0 (en) 2017-03-06 2017-04-19 Cambridge Entpr Ltd Vaccine composition
WO2021059181A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP4136095A1 (en) 2020-04-17 2023-02-22 Regents of the University of Minnesota Sars-cov-2 spike receptor binding domain and compositions and methods thereof
KR20230056727A (ko) 2020-08-26 2023-04-27 화이자 인코포레이티드 B군 스트렙토코쿠스 폴리사카라이드-단백질 접합체, 접합체를 생산하는 방법, 접합체를 포함하는 면역원성 조성물, 및 그의 용도
EP4241791A1 (en) 2022-03-07 2023-09-13 InnaTher Gene Therapy S.à.r.l. Combined gene and radio therapy for the treatment of cancer
EP4241790A1 (en) 2022-03-07 2023-09-13 InnaTher Gene Therapy S.à.r.l. Expression system for the treatment of cancer
WO2024069420A2 (en) 2022-09-29 2024-04-04 Pfizer Inc. Immunogenic compositions comprising an rsv f protein trimer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342828A (en) * 1979-07-20 1982-08-03 Morinaga Milk Industry Co., Ltd. Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells
US4438032A (en) * 1981-01-30 1984-03-20 The Regents Of The University Of California Unique T-lymphocyte line and products derived therefrom
JPS59137417A (ja) * 1983-01-28 1984-08-07 Morinaga Milk Ind Co Ltd 人尿由来コロニ−形成刺激因子及びカリクレインの製造法
JPS59169489A (ja) * 1983-03-15 1984-09-25 Otsuka Pharmaceut Co Ltd ヒト培養株化細胞
AU594014B2 (en) * 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
AU588819B2 (en) * 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
JP3038348B2 (ja) * 1984-11-20 2000-05-08 シェーリング コーポレイション ヒト顆粒状、マクロファージおよび好酸球の細胞増殖因子活性を示すポリペプチドをコードするｃＤＮＡクローン
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
DE3545568A1 (de) * 1985-12-21 1987-07-16 Hoechst Ag Gm-csf-protein, seine derivate, herstellung solcher proteine und ihre verwendung

Also Published As

Publication number Publication date
AU586876B2 (en) 1989-07-27
US5078996A (en) 1992-01-07
CA1341142C (en) 2000-11-21
JPS6289621A (ja) 1987-04-24
DK174603B1 (da) 2003-07-14
DK382986D0 (da) 1986-08-11
EP0211684B1 (en) 1992-07-08
AU6103186A (en) 1987-02-19
DE3685918T2 (de) 1993-02-04
EP0211684A3 (en) 1988-06-08
JPH0780781B2 (ja) 1995-08-30
ATE77958T1 (de) 1992-07-15
EP0211684A2 (en) 1987-02-25
DE3685918D1 (de) 1992-08-13

Similar Documents

Publication Publication Date Title
DK382986D0 (da) Aktivering af makrofag tumoricid aktivitet med granulocytmakrofag kolonistimulationsfaktor
ATE81984T1 (de) Verwendung von granulozyt-makrophagen-kolonie erregenden faktor zur herstellung eines medikaments zur behandlung von bakterieller krankheiten.
DE69333321D1 (de) Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten.
CZ506785A3 (en) Human tumorous necrotic factor, process of its production, dna encoding the human tumorous necrotic factor, a cell transformed by this dna, agent in which the human tumorous necrotic factor is comprised and agent suitable to treating tumors
ATE74510T1 (de) Adoptivimmuntherapie als behandlungsmodalitaet bei menschen.
DE69034018D1 (de) Kombinierte verwendung von hyaluronsäure und therapeutischen wirkstoffen zur verbesserung des therapeutischen effekts
NO880929L (no) Produksjon og bruk av il-6.
Soma et al. Biological Activities of Novel Recombinant Tumor Necrosis Factor Having N-Terminal: Amino Acid Sequences Derived from Cytotoxic Factors Produced by THP-1 Cells
MY106603A (en) Treatment of genital warts with a combination of liquid nitrogen and recombinant dna human alpha interferon
Grimm et al. The lymphokine-activated killer cell phenomenon: in vitro and in vivo studies
Yip et al. Stimulation of lymphokine production by teleocidin, aplysiatoxin, and debromoaplysiatoxin
IE920070A1 (en) Use of IL-4 to enhance the reparative phase of wound healing and repair and to enhance the healing of infected wounds and the wounds of diabetic mammals
JPS6193130A (ja) 低投与量にてヒトの各種病気を系統的に処置するためのγ‐インタフエロン含有剤
MY107071A (en) Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon
Hornicek et al. Production and partial characterization of interleukin 2 induced by periodic acid oxidation of lymphocyte membranes
Van Moorselaar et al. Combined effects of tumor necrosis factor alpha and radiation in the treatment of renal cell carcinoma grown as spheroids
Seki et al. Induction of eosinophil chemotactic factor production from human peripheral blood mononuclear cells by solubilized BALL-1, a B cell lymphoma line
IT1212658B (it) Procedimento per la purificazione di una sostanza fisiologicamente attiva avente attivita antitumorale
Uenoa et al. AB Cell Lymphoma Line, BALL-1 Stimulates! Cells to Produce a Unique Eosinophil Chemotactic Factor
Iwasaka et al. Antitumor activities of human recombinant Interferon‐γ against cervical tumor transplanted into nude mice
DK0409040T3 (da) Kolonistimulerende faktoraktivitetspromotorer
Fujikawa et al. Augmentation of depressed lymphokine activated killer activity by continuous intravenous-administration of recombinant interleukin 2 to patients with hepatocellular carcinoma
ATE111522T1 (de) Methode zur herstellung von rekombinantem menschlichem beta-interleukin-1 in homogener form.
Risser The hospice kind of care: A work of love.
WO1999038523A1 (en) CYTOKINE INDUCERS COMPRISING M161Ag

Legal Events

Date Code Title Description
PUP Patent expired